Jonathan McNeill - 10 Dec 2021 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Senior Vice President of Business Development
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Issuer symbol
DYN
Transactions as of
10 Dec 2021
Net transactions value
$0
Form type
4
Filing time
14 Dec 2021, 15:22:18 UTC
Previous filing
22 Sep 2021
Next filing
14 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Award $0 +25,311 +71% $0.000000 60,947 10 Dec 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock Option (right to buy) Award $0 +37,967 $0.000000 37,967 10 Dec 2021 Common Stock 37,967 $13.12 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of Common Stock issuable under 25,311 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2022.
F2 Includes 38,070 unvested RSUs. Each unvested RSU represents the right to receive one share of Common Stock upon vesting.
F3 This option was granted on December 10, 2021. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2025.

Remarks:

Senior Vice President of Business Development